3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
August 2024 in “JAMA Dermatology” In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.
20 citations
,
July 2024 in “Archives of Dermatological Research” This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.
7 citations
,
April 2024 in “International Journal of Dermatology” Alopecia areata greatly affects the quality of life for children and their families.
April 2024 in “Frontiers in medicine” This Delphi study found that moderate-to-severe alopecia areata in Poland, Czechia, Russia, and Türkiye significantly impacts quality of life and highlights an unmet need for more effective treatments.
2 citations
,
April 2024 in “European Journal of Dermatology” In this study, researchers analyzed data from Spain to find that alopecia areata is more prevalent in adults, with a point prevalence of 0.44% in 2021; they also noted significant healthcare costs and comorbidities, highlighting an unmet treatment need given limited systemic treatment use.
6 citations
,
April 2024 in “Health Science Reports” This study found that young patients with severe AA are more prone to nail abnormalities such as pitting and leukonychia, with koilonychia and red spots lunula in more severe cases.
21 citations
,
February 2024 in “JAMA Dermatology” This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
48 citations
,
July 2023 in “Pediatric Dermatology” This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
9 citations
,
January 2023 in “Dermatology and therapy” This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.
January 2023 in “Journal of The American Academy of Dermatology” This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.
7 citations
,
July 2021 in “JAAD case reports” This review discusses the potential of dupilumab for treating alopecia areata, reporting mixed outcomes with both improvement and new-onset hair loss observed in case reports.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.
19 citations
,
January 2021 in “Journal of the American Academy of Dermatology” This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.
26 citations
,
October 2020 in “Pediatric Dermatology” This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
22 citations
,
June 2017 in “Journal of dermatological treatment” This case series observed that 57% of pediatric patients with alopecia areata experienced significant hair regrowth with methotrexate treatment, which was generally safe, although some results were inconclusive due to follow-up issues.
15 citations
,
May 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.
63 citations
,
January 2017 in “Annals of Dermatology” More research is needed to understand alopecia areata severity.
28 citations
,
July 2015 in “Dermatologic therapy” This study found that combining topical and oral pulse corticosteroid therapy for severe alopecia areata in children led to long-lasting hair regrowth, especially in AA plurifocalis, with no serious side effects reported.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
25 citations
,
June 2015 in “Acta dermato-venereologica” Methotrexate can help some kids with severe hair loss regrow hair.
38 citations
,
January 2013 in “Dermatology” This study found that intravenous high-dose pulse corticosteroids resulted in a complete response in 38% of children with alopecia areata, but the majority of responders relapsed within a year.
38 citations
,
January 2012 in “Journal of Korean Medical Science” This study found that early-onset patients with alopecia universalis or a family history of alopecia areata showed worse prognosis compared to those with late-onset.
70 citations
,
April 2011 in “British journal of dermatology/British journal of dermatology, Supplement” This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.
48 citations
,
July 1998 in “Pediatric Dermatology” This study found that pulsed doses of prednisolone led to excellent hair growth in 60% of young patients with widespread alopecia areata, with minimal side effects.
